LAVA Therapeutics (LVTX)

Company Profile

LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company utilizing its proprietary Gammabody™ platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid and hematologic malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering Vγ9Vδ2 (Vgamma9 Vdelta2) T cell antitumor effector functions upon cross-linking to tumor-associated antigens. LAVA-051, the Company’s lead candidate for the treatment of multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia, is enrolling patients in a Phase 1/2a clinical study (NCT04887259). A Phase 1/2a clinical study to evaluate LAVA-1207 in patients with metastatic castration-resistant prostate cancer (mCRPC) is also enrolling (NCT05369000). For more information, please visit www.lavatherapeutics.com, and follow us on LinkedIn, Twitter and YouTube.

Company profile

Ticker

LVTX

Exchange

NASDAQ

Website

www.lavatherapeutics.com

Incorporated

Netherlands

Location

Netherlands

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Celgene ...

Former names

LAVA Therapeutics BV

SEC CIK

0001840748

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

LVTX stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

6-K

Gamma delta T cell engagers for the development of next - generation cancer therapeutics Corporate presentation January 2023

9 Jan 23

6-K

LAVA Therapeutics Announces Appointment of New Directors to the Board

Annual report (foreign) (amended)

23 Dec 22

CORRESP

Correspondence with SEC

Current report (foreign)

16 Nov 22

6-K

Current report (foreign)

30 Sep 22

6-K

Current report (foreign)

13 Sep 22

6-K

Current report (foreign)

15 Jun 22

Latest ownership filings

Versant Venture Capital VI, L.P.

Cooperatieve Gilde Healthcare IV U.A.

31 Mar 21

Financial summary

Financial statements Chart LVTX financial data

Quarter (USD)	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership, Q3 2022

LVTX institutional ownership history Ownership history

70.6% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	16	20	-20.0%
Opened positions	2	1	+100.0%
Closed positions	6	2	+200.0%
Increased positions	2	1	+100.0%
Reduced positions	2	8	-75.0%

13F shares	Current	Prev Q	Change
Total value	515.20 mm	161.30 mm	+219.4%
Total shares	18.20 mm	18.59 mm	-2.1%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Cooperatieve Gilde Healthcare IV U.A.	5.42 mm	$67.77 mm	0.0%
Versant Venture Capital VI	3.41 mm	$43.27 mm	0.0%
Novo Holdings A/S	3.33 mm	$15.21 mm	0.0%
Redmile	2.82 mm	$12.87 mm	0.0%
SNY Sanofi	1.92 mm	$27.45 mm	0.0%
Silverarc Capital Management	610.81 k	$2.79 mm	NEW
AXAHF Axa	228.67 k	$1.05 mm	+0.5%
Artal	200.00 k	$914.00 k	0.0%
Falcon Edge Capital	121.19 k	$554.00 k	0.0%
Ubs Oconnor	75.00 k	$343.00 mm	NEW

Largest transactions	Shares	Bought/sold	Change
Silverarc Capital Management	610.81 k	+610.81 k	NEW
Nicholas Investment Partners	0.00	-450.56 k	EXIT
Nantahala Capital Management	0.00	-322.98 k	EXIT
DAFNA Capital Management	0.00	-128.34 k	EXIT
Point72 Asset Management	0.00	-111.99 k	EXIT
Ubs Oconnor	75.00 k	+75.00 k	NEW
Millennium Management	39.16 k	-57.24 k	-59.4%
BK Bank Of New York Mellon	0.00	-15.17 k	EXIT
Cannell Capital	17.96 k	+13.90 k	+342.5%
AXAHF Axa	228.67 k	+1.20 k	+0.5%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.